What is severe asthma?

Clinical and Experimental Allergy

Volumn 42, Issue 5, 2012, Pages 617-624

  Blakey, J D ^a   Wardlaw, A J ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Chemokines; Consensus; Definition; Inflammatory lung diseases; Severe asthma

Indexed keywords

ASTHMA; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ASTHMA; DISEASE PROGRESSION; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84859982577     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.03962.x     Document Type: Review

References (88)

1. Harrison B, Stephenson P, Mohan G, Nasser S An ongoing Confidential Enquiry into asthma deaths in the Eastern Region of the UK, 2001-2003. Prim Care Respir J 2005; 14:303-13.
2. Panickar JR, Dodd SR, Smyth RL, Couriel JM Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000. Thorax 2005; 60:1035-8.
3. Bellia V, Pedone C, Catalano F et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest 2007; 132:1175-82.
4. Burney P, Potts J, Ait-Khaled N et al. A multinational study of treatment failures in asthma management. Int J Tuberc Lung Dis 2008; 12:13-8.
5. Mohan G, Harrison BD, Badminton RM, Mildenhall S, Wareham NJ A confidential enquiry into deaths caused by asthma in an English health region: implications for general practice. Br J Gen Pract 1996; 46:529-32.
6. Bucknall CE, Slack R, Godley CC, Mackay TW, Wright SC Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994-6. Thorax 1999; 54:978-84.
7. Guite HF, Dundas R, Burney PG Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999; 54:301-7.
8. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78.
9. Ducharme FM, Lasserson TJ, Cates CJ Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006; 4:CD003137.
10. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 5:CD005535.
11. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; 1:CD002738.
12. Van Ganse E, Antonicelli L, Zhang Q et al. Asthma-related resource use and cost by GINA classification of severity in three European countries. Respir Med 2006; 100:140-7.
13. Antonicelli L, Bucca C, Neri M et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23:723-9.
14. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007; 62:126-33.
15. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19:61-7.
16. de Marco R, Marcon A, Jarvis D et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 2006; 117:1249-56.
17. Hargreave FE, Nair P The definition and diagnosis of asthma. Clin Exp Allergy 2009; 39:1652-8.
18. Pavord ID, Wardlaw AJ The A to E of airway disease. Clin Exp Allergy 2010; 40:62-7.
19. Wenzel S Severe asthma in adults. Am J Respir Crit Care Med 2005; 172:149-60.
20. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
21. Lotvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-60.
22. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213-4.
23. Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IW Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) 1981; 282:1419-22.
24. Grandordy B, Belmatoug N, Morelle A, De Lauture D, Marsac J Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma. Thorax 1987; 42:65-71.
25. McLeod DT, Capewell SJ, Law J, MacLaren W, Seaton A Intramuscular triamcinolone acetonide in chronic severe asthma. Thorax 1985; 40:840-5.
26. O'Reilly JF, Gould G, Kendrick AH, Laszlo G Domiciliary comparison of terbutaline treatment by metered dose inhaler with and without conical spacer in severe and moderately severe chronic asthma. Thorax 1986; 41:766-70.
27. Stellman JL, Spicer JE, Cayton RM Morbidity from chronic asthma. Thorax 1982; 37:218-21.
28. International consensus report on diagnosis and treatment of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health. Publication no. 92-3091, March 1992. Eur Respir J 1992;5:601-41.
29. NAEPP. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997.
30. Clark T, Cagnani CB, Bousquet J et al. Global Initiative for Asthma Management and Prevention. Bethesda, MD: National Institute for Health: National Heart Lung and Blood Institute, 2002.
31. Liard R, Leynaert B, Zureik M, Beguin FX, Neukirch F Using Global Initiative for Asthma guidelines to assess asthma severity in populations. Eur Respir J 2000; 16:615-20.
32. Cockcroft DW, Swystun VA Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:1016-8.
33. Chung KF, Godard P, Adelroth E et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198-208.
34. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341-51.
35. Bousquet J, Clark TJ, Hurd S et al. GINA guidelines on asthma and beyond. Allergy 2007; 62:102-12.
36. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170:836-44.
37. Graham LM Classifying asthma. Chest 2006; 130:13S-20S.
38. Humbert M, Holgate S, Boulet LP, Bousquet J Asthma control or severity: that is the question. Allergy 2007; 62:95-101.
39. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353:364-9.
40. NAEPP. Expert panel report 3: guidelines for the diagnosis and management of asthma-full report. Bethesda, MD: National Heart Lung and Blood Institute, 2007.
41. Taylor DR, Bateman ED, Boulet LP et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-54.
42. GINA. Executive, Assembly, GINA Pocket Guide for Asthma Management and Prevention. In: Organization GIfAWH ed., 2010. Available at (accessed October 2011).
43. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2008; 63(Suppl. 4):iv1-121.
44. Osborne M, Deffebach M The epidemiology and natural history of asthma: outcomes and Treatment Regimens (TENOR) study. Ann Allergy Asthma Immunol 2004; 92:3-4.
45. Abraham B, Antó JM, Barreiro E et al. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470-7.
46. Wan YI, Soler-Artigas M, Shrine NRG et al. A6170: genome-wide association study to identify genetic determinants of severe asthma. Denver, CO: (AUGOSA) American Thoracic Society, 2011.
47. Chanez P, Wenzel SE, Anderson GP et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119:1337-48.
48. Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926-38.
49. Bel EH, Sousa A, Fleming L et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910-17.
50. Wenzel S Characteristics, definition and phenotypes of severe asthma. In: Chung KF, Bel E, Wenzel S eds. ERS monograph: difficult-to-treat severe asthma, Vol. 51. Sheffield, UK: European Respiratory Society, 2011: 50-8.
51. Miller MK, Lee JH, Blanc PD et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006; 28:1145-55.
52. Romagnoli M, Caramori G, Braccioni F et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:552-7.
53. Gaga M, Papageorgiou N, Yiourgioti G et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 2005; 35:954-9.
54. Sorkness RL, Bleecker ER, Busse WW et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104:394-403.
55. Chipps BE, Szefler SJ, Simons FE et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007; 119:1156-63.
56. Kitch BT, Paltiel AD, Kuntz KM et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126:1875-82.
57. Sin DD, Wu L, Man SF The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127:1952-9.
58. Fairs A, Agbetile J, Hargadon B et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182:1362-8.
59. Koppelman GH, Sayers I Evidence of a genetic contribution to lung function decline in asthma. J Allergy Clin Immunol 2011; 128:479-84.
60. ten Brinke A Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 2008; 8:63-9.
61. Bai TR, Vonk JM, Postma DS, Boezen HM Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30:452-6.
62. Barton SJ, Koppelman GH, Vonk JM et al. PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol 2009; 123:1391-400 e17.
63. Soler-Artigas M, Loth DW, Wain LV et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 2011; 43:1082-90.
64. Grainge CL, Lau LC, Ward JA et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011; 364:2006-15.
65. Connolly CK, Prescott RJ The Darlington and Northallerton long term asthma study: pulmonary function. BMC Pulm Med 2005; 5:2.
66. Gershon AS, Wang C, Guan J, To T Burden of comorbidity in individuals with asthma. Thorax 2010; 65:612-8.
67. Price D, Martin RJ, Barnes N et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010; 126:511-8. e1-10.
68. Paggiaro P, Nicolini G, Crimi N et al. Six months step down treatment from high dose ICS/LABA combination therapy in asthma. Denver, CO: American Thoracic Society, 2011.
69. Peters SP, Anthonisen N, Castro M et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-39.
70. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006; 117:563-70.
71. Kersten ET, Driessen JM, Duiverman EJ, Thio BJ The effect of stepping down combination therapy on airway hyperresponsiveness to mannitol. Respir Med 2011; 105:691-7.
72. Melani AS, Bonavia M, Cilenti V et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105:930-8.
73. Horne R Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130:65S-72S.
74. Gamble J, Stevenson M, McClean E, Heaney LG The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180:817-22.
75. Weinstein AG The potential of asthma adherence management to enhance asthma guidelines. Ann Allergy Asthma Immunol 2011; 106:283-91.
76. Barnes P Pathophysiology of asthma. ERS monograph: asthma. Eur Respir Soc 2003; 23:84-113.
77. Siroux V, Boudier A, Bousquet J et al. Phenotypic determinants of uncontrolled asthma. J Allergy Clin Immunol 2009; 124:681-7.
78. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-200.
79. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101:916-21.
80. Ordonez CL, Khashayar R, Wong HH et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001; 163:517-23.
81. Evans CM, Kim K, Tuvim MJ, Dickey BF Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009; 15:4-11.
82. Carroll N, Carello S, Cooke C, James A Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996; 9:709-15.
83. Kuyper LM, Pare PD, Hogg JC et al. Characterization of airway plugging in fatal asthma. Am J Med 2003; 115:6-11.
84. Fahy JV, Dickey BF Airway mucus function and dysfunction. N Engl J Med 2010; 363:2233-47.
85. Rogers DF Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 2004; 4:241-50.
86. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995; 13:748-56.
87. Dolan P, Hallsworth M, Halpern D, King D, Vlaev I MINDSPACE: influencing behaviour through public policy. In: Institute for Government. Introduction: Understanding Why We Act As We Do. London: Cabinet Office, 2010, 11-7.
88. Teague R, Rehmar R, Scott B, Bergh R, Baker L Basic Text (Approval Form). Memphis, TN: Narcotics Anonymous, 1981.